References
- Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. Can Cancer J Clin. 2011;61(2):113–132. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21388967
- Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 38,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–3072.
- Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
- Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol. 2012;2012:973946.
- Pandit S, Bhusal K. Carcinoid syndrome. Treasure Island, FL: StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448096/(2017)
- Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151–160.
- DeVita VT, Rosenberg SA, Lawrence TS, editors. Cancer: principles and practice of oncology 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2014
- Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525–534.
- Broder MS, Chang E, Romanus D, et al. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome. World J Gastroenterol. 2016;22(6):2118–2125.
- Anthony L, Ervin C, Lapuerta P, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158–2168.
- Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;3(1):43–53.
- Shen C, Chu Y, Halperin DM, et al. Carcinoid syndrome and costs of care during the first year after diagnosis of neuroendocrine tumors among elderly patients. Oncologist. 2017;22(12):1451–1462.
- Beaumont JL, Cella D, Phan AT, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461–466.
- Wolin EM, Leydem J, Goldstein G, et al. Patient-reported experience of diagnosis, management and burden of neuroendocrine tumors: results from a large patient survey in the United States. Pancreas. 2017;46:639–647.
- Bureau of Labor Statistics. Employer costs for employee compensation–December 2018. Mar 19, 2019. [cited 2019 Mar 28]. Available from: https://www.bls.gov/news.release/ecec.nr0.htm.
- Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.
- Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11:S17–S26.
- The American Gastroenterological Association. IBS in America: survey summary findings. Dec 2015. [cited 2019 Mar 28]. Available from: http://www.multivu.com/players/English/7634451-aga-ibs-in-america-survey/docs/survey-findings-pdf-635473172.pdf.